Breaking News

Biogen, Sangamo Enter Global Development Pact

By Kristin Brooks | January 9, 2014

To develop therapeutics for hemoglobinopathies

Biogen Idec and Sangamo BioSciences have entered an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, inherited conditions resulting abnormal structure or underproduction of hemoglobin. Biogen will employ its expertise in non-malignant hematology by leveraging Sangamo's zinc finger nuclease (ZFN) genome-editing technology platform to develop treatments targeting sickle cell disease (SCD) and beta-thalassemia. The ZFN technology can be used to precisely target and knock out key regulators of gene expression, or insert a corrective gene to replace the defective copy.
 
Sangamo is responsible for all R&D activities through clinical proof of concept in beta-thalassemia, and both companies will contribute to the submission of an IND application for SCD. Biogen Idec will be responsible for worldwide clinical development and commercialization of any resulting products. Sangamo retains an option to co-promote any licensed product in the U.S.
 
Sangamo will receive an upfront payment of $20 million and will be reimbursed for R&D-related costs. Sangamo is also eligible to receive approximately $300 million based on certain development, regulatory, commercialization, and sales milestones, as well as royalties.
 
"Our collaboration with Sangamo is expected to help us expand our capabilities to develop treatments for people with serious, inherited hematologic conditions," said Douglas E. Williams, Ph.D., Biogen Idec's executive vice president of R&D. "Building upon emerging science related to fetal hemoglobin regulation, we intend to develop Sangamo's novel gene-editing technology to create a single approach that has the potential to functionally cure both sickle cell disease and beta-thalassemia."
 

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers